Prefilled Syringes Market is Anticipated To Reach USD 16.32 Million By 2030

The market for prefilled syringes was estimated to be worth USD 7.22 billion in 2022 and is anticipated to grow to USD 7.91 billion in 2023. By 2030, the market is anticipated to reach USD 16.32 billion, growing at a CAGR of 10.9%. Prefilled syringes can be used to inject drugs and are made to do so via the parental route. The demand for these syringes is expected to increase as more people develop chronic illnesses and other autoimmune diseases. Key players are launching more products, and healthcare professionals are adopting them at a rapid rate.

This information is provided by Fortune Business InsightsTM in its report titled "Prefilled Syringes Market, 2023-2030." The main industrial development was the announcement by Fresenius Kabi AG that Stimufend (pegfilgrastim-fpgk), a medication for chemotherapy patients, will be available in the United States. It's intended to lower the number of infections brought on by febrile neutropenia. The medication comes in a single-dose pre-filled syringe with a passive needle guard and is available in a 6 mg/0.6 mL solution. Additionally, according to Cardinal Health, as of January 2022, the FDA had approved 33 biosimilars, 21 of which were available on the American market. The current self-injection technique is thought to be the administration of parenteral medications using pre-filled injections.